Sorrento Therapeutics (NASDAQ: SRNE) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
Valuation & Earnings
This table compares Sorrento Therapeutics and Pieris Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Sorrento Therapeutics has higher revenue and earnings than Pieris Pharmaceuticals.
This table compares Sorrento Therapeutics and Pieris Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider and Institutional Ownership
25.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 63.1% of Pieris Pharmaceuticals shares are held by institutional investors. 5.0% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 5.1% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Sorrento Therapeutics has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Sorrento Therapeutics and Pieris Pharmaceuticals, as provided by MarketBeat.com.
||Strong Buy Ratings
Sorrento Therapeutics currently has a consensus target price of $15.75, suggesting a potential upside of 148.03%. Pieris Pharmaceuticals has a consensus target price of $12.33, suggesting a potential upside of 137.18%. Given Sorrento Therapeutics’ higher possible upside, research analysts plainly believe Sorrento Therapeutics is more favorable than Pieris Pharmaceuticals.
Sorrento Therapeutics beats Pieris Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.